FFAR4 and obesity disorder: Although further studies are needed to investigate the safety of TUG‐891 and the potential of GPR120 agonists to activate BAT in humans, we thus anticipate that GPR120 agonism is a promising therapeutic strategy to increase BAT activity, thereby increasing fat oxidation and reducing obesity.